title: Regulatory Forum.
abstract: Revision of the International Council for Harmonization (ICH) S1 guidance for rat carcinogenicity studies to be more selective of compounds requiring a 2-year rat carcinogenicity study has been proposed following extensive evaluation of rat carcinogenicity and chronic toxicity studies by industry and drug regulatory authorities. To inform the ICH S1 expert working group in their potential revision of ICH S1, a prospective evaluation study was initiated in 2013, in which sponsors would assess the pharmacologic and toxicologic findings present in the chronic toxicity studies and predict a positive or negative carcinogenicity outcome using a weight of evidence argument (a carcinogenicity assessment document [CAD]). The Scientific and Regulatory Policy Committee was asked by the Society of Toxicology Pathology (STP) executive committee to track these changes with ICH S1 and inform the STP membership of status changes. This commentary is intended to provide a brief summary of recent changes to the CAD guidance and highlight the importance of STP membership participation in the process of CAD submissions.
authors.affiliation: 1 Bristol Myers Squibb Co., Mt. Vernon, IN, USA.
authors.forename: W Michael
authors.initials: WM
authors.lastname: Peden
mesh_terms: D026683:Advisory Committees; D000818:Animals; D015197:Carcinogenicity Tests / Q000379:methods* / Q000592:standards; D003226:Congresses as Topic; D004353:Drug Evaluation, Preclinical / Q000592:standards; D004345:Drug Industry / Q000592:standards*; D023381:Endpoint Determination; D017408:Guidelines as Topic; D007390:International Agencies; D051381:Rats; D012107:Research Design / Q000331:legislation & jurisprudence / Q000592:standards*; D018570:Risk Assessment; D012958:Societies, Scientific
keywords: ICH S1; drug development; preclinical safety assessment/risk management; regulatory affairs